axicabtagene ciloleucel

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Tue, 03/31/20 - 11:05 am
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race
Endpoints
Mon, 07/31/17 - 09:57 am
Kite Pharma
CAR-T
Europe
Novartis
axicabtagene ciloleucel
Kite Pharma partners with Japan's Daiichi for cancer therapy
Yahoo/Reuters
Tue, 01/10/17 - 11:11 am
Kite Pharma
Japan
Daiichi Sankyo
axicabtagene ciloleucel
CAR-T